Evidence map›Paper›PMID 25947148›Full record

ArticleClinical and vaccine immunology : CVI2015

Molecular Engineering of Ghfp, the Gonococcal Orthologue of Neisseria meningitidis Factor H Binding Protein.

Valentina Rippa, Laura Santini, Paola Lo Surdo, Francesca Cantini, Daniele Veggi, Maria Antonietta Gentile, Eva Grassi, Giulia Iannello, Brunella Brunelli, Francesca Ferlicca and 6 more

Open access · diamondAbstract read
In one paragraph

Article in Clinical and vaccine immunology : CVI, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.9field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 8 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 3 institutions in 1 country.

Valentina RippaNovartis Vaccines Srl, a GSK Company, Siena, Italy.
Laura SantiniNovartis Vaccines Srl, a GSK Company, Siena, Italy.
Paola Lo SurdoNovartis Vaccines Srl, a GSK Company, Siena, Italy.
Francesca CantiniCentro Risonanze Magnetiche (CERM) and Department of Chemistry, University of Florence, Sesto Fiorentino, Italy.
Daniele VeggiNovartis Vaccines Srl, a GSK Company, Siena, Italy.
Maria Antonietta GentileNovartis Vaccines Srl, a GSK Company, Siena, Italy.
Eva GrassiNovartis Vaccines Srl, a GSK Company, Siena, Italy.
Giulia IannelloNovartis Vaccines Srl, a GSK Company, Siena, Italy.
Brunella BrunelliNovartis Vaccines Srl, a GSK Company, Siena, Italy.
Francesca FerliccaNovartis Vaccines Srl, a GSK Company, Siena, Italy.
Emiliano PalmieriNovartis Vaccines Srl, a GSK Company, Siena, Italy.
Michele PallaoroNovartis Vaccines Srl, a GSK Company, Siena, Italy.
Beatrice AricòNovartis Vaccines Srl, a GSK Company, Siena, Italy.
Lucia BanciCentro Risonanze Magnetiche (CERM) and Department of Chemistry, University of Florence, Sesto Fiorentino, Italy banci@cerm.unifi.it maria.x.scarselli@gsk.com.
Mariagrazia PizzaNovartis Vaccines Srl, a GSK Company, Siena, Italy.
Maria ScarselliNovartis Vaccines Srl, a GSK Company, Siena, Italy banci@cerm.unifi.it maria.x.scarselli@gsk.com.
Novartis (Italy) · ITToscana Life Sciences · ITUniversity of Florence · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Knowledge of the sequences and structures of proteins produced by microbial pathogens is continuously increasing. Besides offering the possibility of unraveling the mechanisms of pathogenesis at the molecular level, structural information provides new tools for vaccine development, such as the opportunity to improve viral and bacterial vaccine candidates by rational design. Structure-based rational design of antigens can optimize the epitope repertoire in terms of accessibility, stability, and variability. In the present study, we used epitope mapping information on the well-characterized antigen of Neisseria meningitidis factor H binding protein (fHbp) to engineer its gonococcal homologue, Ghfp. Meningococcal fHbp is typically classified in three distinct antigenic variants. We introduced epitopes of fHbp variant 1 onto the surface of Ghfp, which is naturally able to protect against meningococcal strains expressing fHbp of variants 2 and 3. Heterologous epitopes were successfully transplanted, as engineered Ghfp induced functional antibodies against all three fHbp variants. These results confirm that structural vaccinology represents a successful strategy for modulating immune responses, and it is a powerful tool for investigating the extension and localization of immunodominant epitopes.

Indexed as

Protein EngineeringAnimalsAntibodies, BacterialAntigens, BacterialBacterial ProteinsBacterial VaccinesBlood Bactericidal ActivityMiceNeisseria gonorrhoeaeNeisseria meningitidisRecombinant Fusion ProteinsSequence Homology, Amino AcidVaccines, SyntheticVirulence FactorsAntibodies, BacterialAntigens, BacterialBacterial ProteinsBacterial Vaccinesfactor H-binding protein, Neisseria meningitidisRecombinant Fusion ProteinsVaccines, SyntheticVirulence Factors

Identifiers

PMID25947148
PMCPMC4478525
OpenAlexW2099448898

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.